Januvia Drug Classification
Januvia (sitagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, an oral antihyperglycemic medication used for the treatment of type 2 diabetes mellitus. 1
Mechanism of Action
Sitagliptin works by inhibiting the DPP-4 enzyme, which slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. 1
The drug increases and prolongs active incretin levels, which enhances insulin synthesis and release from pancreatic beta cells while reducing hepatic glucose production through lowered glucagon secretion. 1
Sitagliptin demonstrates high selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 at therapeutic concentrations. 1
Clinical Profile
Efficacy Characteristics
DPP-4 inhibitors like sitagliptin provide intermediate glucose-lowering efficacy compared to other antidiabetic drug classes. 2
The medication improves glycemic control through a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP following meals or oral glucose loads. 1
Safety Features
Sitagliptin carries no hypoglycemia risk when used as monotherapy (though risk increases when combined with sulfonylureas or insulin). 2, 3
The medication is weight-neutral, making it advantageous for patients with type 2 diabetes who are concerned about weight gain. 2, 3
Cardiovascular safety was established in the TECOS trial, where sitagliptin was noninferior to placebo for major adverse cardiac events in patients with established cardiovascular disease. 4
Common Pitfalls and Caveats
Dose adjustment is required in patients with renal impairment, as sitagliptin is substantially excreted by the kidney; renal function should be assessed before initiating therapy and periodically thereafter, especially in elderly patients. 1
Pancreatitis cases have been reported with DPP-4 inhibitors including sitagliptin, though a causal relationship has not been established; the drug should be discontinued if pancreatitis is suspected. 2
When combined with sulfonylureas, the sulfonylurea dose may need reduction to minimize hypoglycemia risk. 2